Delcath Systems (NASDAQ:DCTH) Stock Price Target Raised at BTIG Research

Delcath Systems (NASDAQ:DCTH) had its price objective hoisted by investment analysts at BTIG Research from $21.00 to $25.00 in a report released on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research‘s price target would suggest a potential upside of 30.10% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on DCTH. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price (up from $30.00) on shares of Delcath Systems in a research note on Friday, August 7th. Wall Street Zen upgraded shares of Delcath Systems from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings cut shares of Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. Finally, Zacks Research downgraded shares of Delcath Systems from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 6th. Two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Delcath Systems currently has an average rating of “Moderate Buy” and an average price target of $28.00.

Delcath Systems Price Performance

Shares of NASDAQ DCTH traded up $4.29 during mid-day trading on Monday, hitting $19.22. The company had a trading volume of 974,868 shares, compared to its average volume of 456,424. Delcath Systems has a 12 month low of $8.12 and a 12 month high of $19.35. The stock has a market cap of $666.78 million, a price-to-earnings ratio of 1,922.02 and a beta of 0.62. The firm’s 50 day simple moving average is $15.45 and its two-hundred day simple moving average is $12.44.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Monday, November 9th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.26. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%. The firm had revenue of $35.10 million during the quarter, compared to the consensus estimate of $25.99 million. Equities analysts forecast that Delcath Systems will post -0.17 earnings per share for the current year.

Hedge Funds Weigh In On Delcath Systems

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. grew its holdings in Delcath Systems by 31.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company’s stock worth $1,417,000 after buying an additional 21,069 shares in the last quarter. Alps Advisors Inc. increased its position in Delcath Systems by 30.3% in the 3rd quarter. Alps Advisors Inc. now owns 45,640 shares of the company’s stock valued at $729,000 after acquiring an additional 10,600 shares during the period. Kopp Family Office LLC acquired a new stake in Delcath Systems in the 3rd quarter valued at approximately $450,000. Integrated Wealth Concepts LLC bought a new stake in Delcath Systems during the 2nd quarter valued at $48,000. Finally, IFP Advisors Inc bought a new stake in Delcath Systems during the 2nd quarter valued at $52,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.

Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company’s proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.

Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand.